PlainRecalls
FDA Devices Moderate Class II Terminated

Chembio DPP COVID-19 IgM/IgG System- Rrapid immunochromatographic test for the qualitative detection and differentiation of Immunoglobulin M (IgM) and Immunoglobulin G (IgG) antibodies to SARS-CoV-2 in fingerstick whole blood, venous whole blood, serum, or plasma (lithium heparin or EDTA. Model Number: 65-9569-0

Reported: August 26, 2020 Initiated: June 18, 2020 #Z-2807-2020

Product Description

Chembio DPP COVID-19 IgM/IgG System- Rrapid immunochromatographic test for the qualitative detection and differentiation of Immunoglobulin M (IgM) and Immunoglobulin G (IgG) antibodies to SARS-CoV-2 in fingerstick whole blood, venous whole blood, serum, or plasma (lithium heparin or EDTA. Model Number: 65-9569-0

Reason for Recall

FDA revocation of the Emergency Use Authorization due to performance issues

Details

Recalling Firm
Chembio Diagnostics, Inc
Units Affected
7,674 kits (153,480 devices)
Distribution
Nationwide
Location
Medford, NY

Frequently Asked Questions

What product was recalled?
Chembio DPP COVID-19 IgM/IgG System- Rrapid immunochromatographic test for the qualitative detection and differentiation of Immunoglobulin M (IgM) and Immunoglobulin G (IgG) antibodies to SARS-CoV-2 in fingerstick whole blood, venous whole blood, serum, or plasma (lithium heparin or EDTA. Model Number: 65-9569-0. Recalled by Chembio Diagnostics, Inc. Units affected: 7,674 kits (153,480 devices).
Why was this product recalled?
FDA revocation of the Emergency Use Authorization due to performance issues
Which agency issued this recall?
This recall was issued by the FDA Devices on August 26, 2020. Severity: Moderate. Recall number: Z-2807-2020.